<DOC>
	<DOCNO>NCT01096030</DOCNO>
	<brief_summary>This uncontrolled , open-label , non-randomized , phase I study . The primary objective study define pharmacokinetics ( PK ) evaluate safety tolerability Regorafenib administer orally single agent Chinese patient advance solid tumor . The secondary objective evaluate tumor response patient treat Regorafenib .</brief_summary>
	<brief_title>Phase I Study BAY73-4506 Chinese Patients With Advanced , Refractory Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Male female Chinese subject &gt; / 18 year Advanced , histologically cytologically confirm solid tumor Subjects malignancy must refractory standard treatment standard therapy available , subject actively refuse treatment would regard standard , and/or , judgment investigator his/her designate associate ( ) , experimental treatment clinically ethically acceptable . Eastern Cooperative Oncology Group performance status ( ECOGPS ) 01 ; Adequate bone marrow , liver renal function Life expectancy least 3 month Unstable/uncontrolled cardiac disease History arterial venous thrombotic embolic event Malabsorption condition Severe renal impairment ; persistent proteinuria &gt; /= Grade 3 Symptomatic metastatic brain meningeal tumor Clinically significant bleeding &gt; /=Grade 3 within 30 day start study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Advanced</keyword>
	<keyword>Refractory solid tumor</keyword>
</DOC>